PPD and the Global Allergy and Asthma European Network (GA2LEN) have entered a strategic alliance under which PPD will have access to GA2LEN’s allergy and asthma experts and more than 100 allergy and asthma sites in Europe. PPD and GA2LEN will work to reduce study start-up times, increase patient recruitment for trials, and provide the Resources and training to increase the number of physicians and support staff conducting research.
"This agreement supports our strategy to establish collaborations across a wide range of therapeutic areas," said Paul Colvin, executive vice president of global clinical development for PPD. "The large size of this network, coupled with its extensive scientific expertise, strengthens our capabilities as a full development respiratory partner by increasing our ability to recruit sites and patients into allergy and asthma trials."
"Allergies and asthma are Europe's most common chronic diseases, and their prevalence is growing," said Professor Torsten Zuberbier, secretary general for GA2LEN. "As a consortium of more than 100 leading European partners and multidisciplinary research centers specializing in allergic diseases, we conduct wide-ranging studies across Europe involving patients who face varying environmental and lifestyle impacts. This alliance with PPD builds our reputation as a leader in allergy and asthma treatment, as we will better understand the evolution and development of allergic diseases and how to treat them more effectively."